A61P 39 - General protective or antinoxious agents

Patents for A61P 39 - General protective or antinoxious agents (19,019)
12/2002
12/18/2002	EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002	EP1265628A1 Use of human not1 and not1a orphan receptors
12/18/2002	EP1265595A2 Stabilized ascorbic acid solutions
12/17/2002	US6495604 Cycloalkene derivatives, process for producing the same, and use
12/17/2002	US6495565 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition
12/17/2002	US6495552 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid.
12/17/2002	US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002	CA2144398C Composition containing a non photocatalytic metal oxide and tocopherol; use thereof in cosmetic and/or dermatological applications and processes implementing said composition
12/12/2002	WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002	WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	WO2002098431A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
12/12/2002	WO2002076494A3 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
12/12/2002	US20020188281 Stabilized bioactive preparations and method of use
12/12/2002	US20020188134 Pharmaceutical compositions
12/12/2002	US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002	US20020187936 Methods of treating liver disease and liver damage with growth hormone and foxM1B
12/12/2002	US20020187152 Administering a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells; vaccines, diagnosis, screening
12/12/2002	DE10125883A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the context of renal replacement therapy
12/12/2002	CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002	CA2449024A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
12/11/2002	EP1264827A1 Process for the preparation of Tosylbenzylformamides
12/11/2002	EP1263756A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263470A1 METHOD FOR PRODUCING A COENZYME Q10 / $g(g)-CYCLODEXTRIN COMPLEX
12/11/2002	EP1263464A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function
12/11/2002	EP1263430A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases
12/11/2002	EP1263427A1 Il-8 receptor antagonists
12/11/2002	CN1384829A Sodium-hydrogen exchanger type 1 inhibitor crystals
12/11/2002	CN1384750A Plant extract mixtures and their uses
12/11/2002	CN1384738A Transdermal drug delivery devices
12/11/2002	CN1384733A Dry powder compositions having improved dispersivity
12/11/2002	CN1383819A Protocyanidin slow release capsule
12/10/2002	US6492408 Peptidomimetic inhibitors of intercellular adhesion molecules binding to leukointegrins, such as lfa-1 and mac-1
12/10/2002	US6491948 Increased bioavailability; preventing oxidative destabilization of dnas, rnas and proteins involved in neuronal memory processes;neuroprotective agents possessing preventive properties against memory dysfunctions
12/10/2002	US6491933 Personal care articles comprising hotmelt compositions
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096912A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096414A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002009685A1 Preparation with vascular protective and anti-oxidative effect and use thereof
12/05/2002	WO2001088085A3 Novel bee venom polypeptides and methods of use thereof
12/05/2002	US20020183300 Zinc ionophores as anti-stress agents
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	CA2455341A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	CA2411907A1 Preparation with vascular protective and anti-oxidative effect and use thereof
12/04/2002	EP1261349A1 Compounds with chelation affinity and selectivity for first transition series elements and their use
12/04/2002	EP1261329A2 Il-8 receptor antagonists
12/04/2002	EP1261322A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
12/03/2002	US6489514 (-)-Secoisolariciresinol as an antioxidant obtained from a new natural source namely stereospermum personatum
12/03/2002	US6489326 Sodium nucleinate, 2-amino-1,2,3,4-tetrahydrophthalazine-1,4-dione sodium salt dihydrate, used as an immunomodulator, which also has antiinflammatory and antioxidant properties
11/2002
11/28/2002	WO2002094980A2 Phytocystatin
11/28/2002	WO2002094263A2 Caspase inhibitors and uses thereof
11/28/2002	WO2002094019A1 Highly purified antiendotoxin compound
11/28/2002	WO2002085897A8 Heterocyclic compounds for aging-related and diabetic vascular complications
11/28/2002	WO2001089542A3 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/28/2002	US20020177622 Neuroprotectants; enhancing cognition
11/28/2002	US20020176903 Comprising an olive plant extract
11/28/2002	US20020176840 A porous spherical carbonaceous substance has a diameter 0.01 to 1 mm, and a specific surface area, excellent adsorbability of harmful toxins in gastrointestinal tracts; treating patients with liver or renal diseases
11/28/2002	US20020176818 Radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
11/27/2002	EP1259493A2 Substituted piperazine compounds
11/27/2002	EP1259489A1 Aryl fused azapolycyclic compounds
11/27/2002	EP1259470A2 A group of anti-cancer compounds with specific structure and their production method
11/27/2002	EP1112005B1 Antioxidant composition comprising acetyl l-carnitine and alpha-lipoic acid
11/27/2002	EP0984915A4 Lutein esters having high bioavailability
11/27/2002	EP0910360B1 Reduction of cardiotoxicity of an antitumor agent using manganese compound
11/27/2002	CN1382134A Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them
11/27/2002	CN1382052A Use of dipyridazole or mopidamol in the manufacture of a medicament for treatment and prevention of fibrin-dependent microcirculation disorders
11/27/2002	CN1381235A Baokang capsule as natural health-care product
11/26/2002	US6486125 Synthesis of soluble β-sheet forming peptides
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485755 Methods of using electron active compounds for managing cancer
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	WO2002092597A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	WO2002092576A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	WO2002092103A1 Chemoprotection using amifostine and related compounds
11/21/2002	WO2002092077A2 Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
11/21/2002	WO2002092075A2 Therapeutic delivery of carbon monoxide
11/21/2002	WO2002092013A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002	WO2002078615A3 Antioxidant nitroxides and nitrones as therapeutic agents
11/21/2002	WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173500 Hypotensive agents; antiischemic agents
11/21/2002	US20020173499 Estrogen replacement therapy
11/21/2002	US20020173449 O-superfamily conotoxin peptides
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447275A1 Therapeutic delivery of carbon monoxide
11/21/2002	CA2447116A1 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	CA2446988A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	CA2446736A1 Chemoprotection using amifostine and related compounds
11/21/2002	CA2446586A1 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	CA2445003A1 Diarylurea derivatives useful as anti-inflammatory agents

1 ... 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 ... 191